Literature DB >> 19688776

Cell based therapy for Duchenne muscular dystrophy.

Andrea Farini1, Paola Razini, Silvia Erratico, Yvan Torrente, Mirella Meregalli.   

Abstract

Mutations in the dystrophin gene cause an X-linked genetic disorder: Duchenne muscular dystrophy (DMD). Stem cell therapy is an attractive method to treat DMD because a small number of cells are required to obtain a therapeutic effect. Here, we discussed about multiple types of myogenic stem cells and their possible use to treat DMD. The identification of a stem cell population providing efficient muscle regeneration is critical for the progression of cell therapy for DMD. We speculated that the most promising possibility for the treatment of DMD is a combination of different approaches, such as gene and stem cell therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19688776     DOI: 10.1002/jcp.21895

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  25 in total

Review 1.  Building muscle: molecular regulation of myogenesis.

Authors:  C Florian Bentzinger; Yu Xin Wang; Michael A Rudnicki
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-02-01       Impact factor: 10.005

2.  Systemic delivery of allogenic muscle stem cells induces long-term muscle repair and clinical efficacy in duchenne muscular dystrophy dogs.

Authors:  Karl Rouger; Thibaut Larcher; Laurence Dubreil; Jack-Yves Deschamps; Caroline Le Guiner; Gregory Jouvion; Bruno Delorme; Blandine Lieubeau; Marine Carlus; Benoît Fornasari; Marine Theret; Priscilla Orlando; Mireille Ledevin; Céline Zuber; Isabelle Leroux; Stéphane Deleau; Lydie Guigand; Isabelle Testault; Elisabeth Le Rumeur; Marc Fiszman; Yan Chérel
Journal:  Am J Pathol       Date:  2011-09-13       Impact factor: 4.307

Review 3.  Duchenne muscular dystrophy: current cell therapies.

Authors:  Dorota Sienkiewicz; Wojciech Kulak; Bożena Okurowska-Zawada; Grażyna Paszko-Patej; Katarzyna Kawnik
Journal:  Ther Adv Neurol Disord       Date:  2015-07       Impact factor: 6.570

4.  Myogenic potential of human alveolar mucosa derived cells.

Authors:  Vadim L Zorin; Andrey A Pulin; Ilya I Eremin; Ivan N Korsakov; Alla I Zorina; Natalia V Khromova; Olga I Sokova; Konstantin V Kotenko; Pavel B Kopnin
Journal:  Cell Cycle       Date:  2017-01-24       Impact factor: 4.534

Review 5.  Extrinsic regulation of satellite cell specification.

Authors:  C Florian Bentzinger; Julia von Maltzahn; Michael A Rudnicki
Journal:  Stem Cell Res Ther       Date:  2010-08-26       Impact factor: 6.832

Review 6.  Engineering skeletal muscle repair.

Authors:  Mark Juhas; Nenad Bursac
Journal:  Curr Opin Biotechnol       Date:  2013-05-24       Impact factor: 9.740

7.  Activation of Wnt3a signaling promotes myogenic differentiation of mesenchymal stem cells in mdx mice.

Authors:  Yan-Chang Shang; Shu-Hui Wang; Fu Xiong; Fu-Ning Peng; Zhen-Shan Liu; Jia Geng; Cheng Zhang
Journal:  Acta Pharmacol Sin       Date:  2016-05-02       Impact factor: 6.150

8.  Genome Therapy of Myotonic Dystrophy Type 1 iPS Cells for Development of Autologous Stem Cell Therapy.

Authors:  Yuanzheng Gao; Xiuming Guo; Katherine Santostefano; Yanlin Wang; Tammy Reid; Desmond Zeng; Naohiro Terada; Tetsuo Ashizawa; Guangbin Xia
Journal:  Mol Ther       Date:  2016-05-12       Impact factor: 11.454

9.  Recent developments in the treatment of Duchenne muscular dystrophy and spinal muscular atrophy.

Authors:  Wendy K M Liew; Peter B Kang
Journal:  Ther Adv Neurol Disord       Date:  2013-05       Impact factor: 6.570

10.  Therapy of Genetic Disorders-Novel Therapies for Duchenne Muscular Dystrophy.

Authors:  Jane T Seto; Niclas E Bengtsson; Jeffrey S Chamberlain
Journal:  Curr Pediatr Rep       Date:  2014-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.